Retevmo Trial Yields Event-Free Survival Gain; Shares Fall on Wegovy Price Cuts
Eli Lilly’s Retevmo achieved a significant event-free survival benefit in its Phase 3 LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer, with results due at a medical congress. Lilly shares declined after Novo Nordisk announced 2027 price cuts for Wegovy and Ozempic, heightening obesity market competition.
1. LIBRETTO-432 Trial Results
Eli Lilly’s Phase 3 LIBRETTO-432 trial evaluated Retevmo as adjuvant therapy in early-stage RET fusion-positive non-small cell lung cancer. The study demonstrated a significant improvement in event-free survival compared with standard of care, and full data will be presented at an upcoming medical congress for regulatory discussions.
2. Competitive Pressure from Price Cuts
Lilly shares declined after Novo Nordisk announced plans to reduce Wegovy and Ozempic prices starting in 2027. The anticipated price cuts could intensify competition in the weight-loss market, potentially compressing revenue growth for Lilly’s obesity treatment portfolio.